Nashville-based ophthalmology company Harrow Health has bought the exclusive commercial rights of four U.S. Food and Drug Administration-approved eye drops for $14 million.

The company bought ophthalmic-focused products that will help expand its surgical and acute care market presence, including Novartis brand names Iopidine, Maxitrol and Moxeza. 

Harrow Health